IL5 and vasculitis: Such mixed patterns reflect converging biology—type 2 inflammation plus humoral autoimmunity—and often require stepwise or combined therapy: treat vasculitis first (rituximab ± cyclophosphamide) when organ-threatening, and add IL-5/IL-5Rα blockade for eosinophil-driven control and glucocorticoid sparing [16,23].